3.4.24.23 (-)-5-hydroxypluviatolide 50% inhibition at 0.05 mM 131773 3.4.24.23 (-)-catechin-3-gallate - 33806 3.4.24.23 (-)-catechin-3-gallate inhibition is un affected by presence of 10 mM CaCl2 33806 3.4.24.23 (-)-epicatechin-3-gallate - 17280 3.4.24.23 (-)-epicatechin-3-gallate inhibition is un affected by presence of 10 mM CaCl2 17280 3.4.24.23 (-)-epigallo-3-catechin gallate - 54407 3.4.24.23 (-)-epigallocatechin-3-gallate inhibitory effect is increased on presence of 10 mM CaCl2, no interaction with Cl- 2518 3.4.24.23 (-)-gallocatechin-3-gallate - 33807 3.4.24.23 (-)-gallocatechin-3-gallate inhibitory effect is increased on presence of 10 mM CaCl2, no interaction with Cl- 33807 3.4.24.23 (-)-haplomyrfolin 50% inhibition at 0.1 mM 131770 3.4.24.23 (-)-hinokinin 50% inhibition at 0.1 mM 131771 3.4.24.23 (-)-thujaplicatin-d3 50% inhibition at 0.08 mM 131772 3.4.24.23 (4-phenyl-1,4-dihydropyridine-3,5-diyl)dimethanol - 204644 3.4.24.23 1,10-phenanthroline - 62 3.4.24.23 1-(4-methoxyphenyl)sulfonyl-4-(tert-butoxycarbonyl)-piperazine-2-carboxylic acid - 118108 3.4.24.23 1-butanol - 556 3.4.24.23 2-butanol - 1132 3.4.24.23 2-methyl-1-propanol - 5472 3.4.24.23 2-methyl-2-butanol - 30566 3.4.24.23 2-Methyl-2-propanol - 10488 3.4.24.23 3,9-di(4-methoxylphenyl)-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205016 3.4.24.23 3,9-di(4-methylphenyl)-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205017 3.4.24.23 3,9-dibenzyl-1,5,7,11-tetrahydroxymethyl-6,12-di(2,3,4-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane - 205018 3.4.24.23 3,9-dibenzyl-1,5,7,11-tetrahydroxymethyl-6,12-di(2,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane - 205019 3.4.24.23 3,9-dibenzyl-1,5,7,11-tetrahydroxymethyl-6,12-di(2,4-dimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane - 205020 3.4.24.23 3,9-dibenzyl-1,5,7,11-tetrahydroxymethyl-6,12-di(4-hydroxyphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane - 205021 3.4.24.23 3,9-dibenzyl-6,12-di(2,3,4-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205022 3.4.24.23 3,9-dibenzyl-6,12-di(2,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205023 3.4.24.23 3,9-dibenzyl-6,12-di(2,4-dimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205024 3.4.24.23 3,9-dibenzyl-6,12-di(3,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205025 3.4.24.23 3,9-dibenzyl-6,12-di(4-hydroxyphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205026 3.4.24.23 3,9-dibenzyl-6,12-di(4-methoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205027 3.4.24.23 3,9-dibenzyl-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205028 3.4.24.23 3,9-diphenyl-6,12-di(4-fluoridephenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205029 3.4.24.23 3,9-diphenyl-6,12-di(4-hydroxyphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205030 3.4.24.23 3,9-diphenyl-6,12-di(4-methoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205031 3.4.24.23 3,9-diphenyl-6,12-di(4-methylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205032 3.4.24.23 3,9-diphenyl-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205033 3.4.24.23 3.9-diphenyl-6,12-di(3,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205108 3.4.24.23 6,12-di(2,3,4-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205340 3.4.24.23 6,12-di(2,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205341 3.4.24.23 6,12-di(2,4-dimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205342 3.4.24.23 6,12-di(3,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205343 3.4.24.23 6,12-di(4-hydroxyphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205344 3.4.24.23 6,12-di(4-methoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205345 3.4.24.23 6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate - 205346 3.4.24.23 Ag-3340 - 59871 3.4.24.23 andrographolide a diterpenoid lactone isolated from a traditional herbal medicine Andrographis paniculata, downregulates MMP-7 in colorectal carcinoma LoVo cells leading to inhibition of cell migration and invasion, overview 160256 3.4.24.23 batimastat i.e. BB-94, BB-94 significantly reduces the amount of N-cadherin fragment produced in response to Fas-L 4135 3.4.24.23 batimastat - 4135 3.4.24.23 BB-94 [4-(N-hydroxyamino)-(2R)-isobutyl-(3S)-(thienylthiomethyl)-succinyl]-L-Phe-N-methylamine 35845 3.4.24.23 Brij-35 activates MMP-7 in a broad concentration range, but inhibits at high concentration 6718 3.4.24.23 carboxylate - 12465 3.4.24.23 cardiolipin associates with the enzyme at the cell surface and inhibits by 92% 813 3.4.24.23 Cholesterol sulfate non-competitive inhibition, decreases the enzyme's thermostability, inhibition mechanism, overview 6498 3.4.24.23 Cholesterol sulfate associates with the enzyme st the cell surface and modulates the substrate preference of the enzyme, 20% inhibition 6498 3.4.24.23 diethyl 1-phenoxy-4-(4-propylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate - 205414 3.4.24.23 diethyl 4-(2-methoxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylate - 205415 3.4.24.23 diethyl 4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate - 205416 3.4.24.23 diethyl 4-(3-methoxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylate - 205417 3.4.24.23 diethyl 4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate - 205418 3.4.24.23 diethyl 4-(4-methylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate - 205419 3.4.24.23 diethyl 4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate - 205420 3.4.24.23 diethyl 4-(4-nitrophenyl)-1-phenoxy-1,4-dihydropyridine-3,5-dicarboxylate - 205421 3.4.24.23 diethyl 4-(4-propylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate - 205422 3.4.24.23 diethyl 4-[4-(5-methoxypentyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate - 205423 3.4.24.23 diethyl 4-[4-(5-methoxypentyl)phenyl]-1-phenoxy-1,4-dihydropyridine-3,5-dicarboxylate - 205424 3.4.24.23 dimethyl sulfoxide competitive inhibition 1217 3.4.24.23 DTT - 177 3.4.24.23 EDTA - 21 3.4.24.23 EDTA inhibits MMP-7-induced cell aggregation 21 3.4.24.23 fibronectin 1 fibronectin 1, interacts with MMP-7 160257 3.4.24.23 GM6001 - 1952 3.4.24.23 GM6001 a broad-spectrum MMP inhibitor 1952 3.4.24.23 green tea catechin - 118155 3.4.24.23 Hydroxamate - 4019 3.4.24.23 KB-R7785 - 22117 3.4.24.23 marimastat - 3900 3.4.24.23 methyl 1-(4-methoxyphenyl)sulfonyl-4-(N-methyl-N-hexylaminocarbonyl)piperazine-2-carboxylate - 118142 3.4.24.23 methyl 1-(4-methoxyphenyl)sulfonyl-4-(tert-butoxycarbonyl)piperazine-2-carboxylate - 118120 3.4.24.23 methyl 1-(4-methoxyphenyl)sulfonyl-4-acetylpiperazine-2-carboxylate - 118125 3.4.24.23 methyl 1-(4-methoxyphenyl)sulfonyl-4-amidopiperazine-2-carboxylate - 118139 3.4.24.23 methyl 1-(4-methoxyphenyl)sulfonyl-4-cyclohexanecarbonylpiperazine-2-carboxylate - 118127 3.4.24.23 methyl 1-(4-methoxyphenyl)sulfonyl-4-methylpiperazine-2-carboxylate - 118110 3.4.24.23 methyl 1-(4-methoxyphenyl)sulfonyl-4-methylsulfonylpiperazine-2-carboxylate - 118116 3.4.24.23 methyl 1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxylate hydrochloride - 118109 3.4.24.23 methyl 4-[4-(4-bromophenyl)thiazol-2-yl]-1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxylate - 118114 3.4.24.23 methyl-beta-cyclodextrin inhibits release of the HAI-1 fragment by MMP-7-catalyzed cleavage 11065 3.4.24.23 MMPI-II a small synthetic inhibitor of 514 Da 37418 3.4.24.23 additional information not: phosphoramidon; Zincov 2 3.4.24.23 additional information examination of inhibitor-enzyme complexes emphasizes the dominant role the zinc-coordination group plays in determining the relative potencies of their inhibitors 2 3.4.24.23 additional information two zinc and two calciums are required for inhibitor binding 2 3.4.24.23 additional information no inhibition with phosphoramidon 2 3.4.24.23 additional information for lignans, dibenzylbutyryrolactone structure is essential for inhibitory effect 2 3.4.24.23 additional information estrogen acidification of the luminal solution tends to alkalinize exocytotic vesicles and may lead to decreased activation of the MMP-7 2 3.4.24.23 additional information MMP-7 interacts with anionic, cationic and neutral lipid membranes, while the catalytic activity of the enzyme remains unaffected upon binding to neutral and negatively charged membranes, it is drastically impaired upon binding to the positively charged membranes, overview 2 3.4.24.23 additional information angiogenesis and apoptosis do not influence MMP-7 expression in lung cancer cells, overview 2 3.4.24.23 additional information inhibition of hyaluronan synthases HAS2 and HAS3 highly decreases MMP-7 expression and activity in SW620 cells 2 3.4.24.23 additional information MMP-7 knockout or inhibition retards cleavage of N-cadherin and vascular smooth muscle cell apoptosis, overview 2 3.4.24.23 additional information green tea catechins inhibit MMP-7 competitively and the galloyl group is essential, differences result from the B-ring, mechanism of inhibition 2 3.4.24.23 additional information design, synthesis and biological evaluation of 3,9-diazatetraasteranes as matrilysin inhibitors, molceular docking and simulations, overview. Common interaction mechanism of 3,9-diazatetraasteranes with the catalytic site of matrilysin 2 3.4.24.23 additional information the internal four residues Ile29, Arg33, Arg51 and Trp55 of MMP-7 are important for binding of inhibitory acidic lipids, overview 2 3.4.24.23 additional information nitro-based selective inhibitors against matrix metalloproteinase-7, overview. Kinetics and active-site-binding mode of the inhibitors, molecular docking. A reasonable adjustment of the P'3 side chains of the nitro-based MMP inhibitors could improve selectivity for the inhibition of MMP-7 over MMP-1 (EC 3.4.24.7) 2 3.4.24.23 additional information the enzyme contains an auto-inhibitory peptide 2 3.4.24.23 N-alkylpiperazine - 118106 3.4.24.23 N-hydroxy-1,4-bis(4-methoxyphenylsulfonyl)piperazine-2-carboxamide - 118117 3.4.24.23 N-hydroxy-1-(4-bromophenyl)sulfonyl-4-(N-methyl-N-hexylaminocarbonyl)piperazine-2-carboxamide - 118144 3.4.24.23 N-hydroxy-1-(4-bromophenyl)sulfonyl-4-(S)-(2-hydroxy-3-methyl-1-oxobutyl)piperazine-2-carboxamide - 118130 3.4.24.23 N-hydroxy-1-(4-bromophenyl)sulfonyl-4-[N-bis(2-methoxyethyl)aminocarbonyl]piperazine-2-carboxamide - 118154 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(1-oxohexyl)piperazine-2-carboxamide - 118129 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(2-phenylethylaminocarbonyl)piperazine-2-carboxamide - 118148 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(3-ethoxy-1-propoxycarbonyl)piperazine-2-carboxamide - 118124 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(3-methoxyphenylaminocarbonyl)piperazine-2-carboxamide - 118149 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(3-pyridinylmethoxycarbonyl)piperazine-2-carboxamide - 118123 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(4-biphenylcarbonyl)piperazine-2-carboxamide - 54406 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(4-methyl-1,2,3-thiadiazole-5-carbonyl)piperazine-2-carboxamide - 118137 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(4-morpholinylcarbonyl)piperazine-2-carboxamide - 118152 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(5-methyl-3-phenylisoxazole-4-carbonyl)piperazine-2-carboxamide - 118138 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(isoxazole-5-carbonyl)piperazine-2-carboxamide - 118136 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(n-hexyl)piperazine-2-carboxamide - 118112 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(n-hexylaminocarbonyl)piperazine-2-carboxamide - 118141 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(N-methyl-N-hexylaminocarbonyl)piperazine-2-carboxamide - 118143 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(N-methyl-N-phenylmethylaminocarbonyl)piperazine-2-carboxamide - 118147 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(N-methylpiperazine-1N-carbonyl)piperazine-2-carboxamide hydrochloride - 118153 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(N-propyl-N-cyclopropylmethyl aminocarbonyl)piperazine-2-carboxamide - 118150 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(tert-butoxycarbonyl)piperazine-2-carboxamide - 118121 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-acetylpiperazine-2-carboxamide - 118126 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-amidopiperazine-2-carboxamide - 118140 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzoylpiperazine-2-carboxamide - 118132 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzylcarbamoylpiperazine-2-carboxamide - 118145 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzyloxycarbonylpiperazine-2-carboxamide - 118122 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzylthiocarbamoylpiperazine-2-carboxamide - 118146 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-cyclohexanecarbonylpiperazine-2-carboxamide - 118128 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-furoylpiperazine-2-carboxamide - 118135 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-methylpiperazine-2-carboxamide - 118111 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-nicotinoylpiperazine-2-carboxamide hydrochloride - 118133 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-phenoxyacetylpiperazine-2-carboxamide - 118131 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-phenylmethylpiperazine-2-carboxamide - 118113 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-thiophenecarbonylpiperazine-2-carboxamide - 118134 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]piperazine-2-carboxamide - 118119 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-[(hexahydro-1H-azepin-1-yl)carbonyl]piperazine-2-carboxamide - 118151 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-[2-amino-4-methyl-5-thiazolylsulfonyl]piperazine-2-carboxamide - 118118 3.4.24.23 N-hydroxy-1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxamide - 118107 3.4.24.23 N-hydroxy-4-[4-(4-bromophenyl)thiazol-2-yl]-1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxamide - 118115 3.4.24.23 N-[3-[3,5-bis(hydroxymethyl)-1,4-dihydropyridin-4-yl]phenyl]acetamide - 205763 3.4.24.23 N-[3-[3,5-bis(hydroxymethyl)-1-phenoxy-1,4-dihydropyridin-4-yl]phenyl]acetamide - 205764 3.4.24.23 N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-(naphthalen-2-yl)-L-alanyl-N-(2-aminoethyl)-L-alaninamide i.e. TAPI-1, a hydroxamate-based metalloproteinase inhibitor 167959 3.4.24.23 o-phenanthroline - 239 3.4.24.23 Ovostatin - 31259 3.4.24.23 Pseudopeptide inhibitors - 98602 3.4.24.23 R-94138 - 54408 3.4.24.23 RRS269 - 205845 3.4.24.23 Sulfatide associates with the enzyme at the cell surface and inhibits by 80% 15976 3.4.24.23 Sulfodiimine - 97193 3.4.24.23 sulindac in sulindac-treated ApcMin/+ mice, a genetic model of human familial adenomatous polyposis, collagen genes, viz. Col1a2, Col5a2, Col6a2, and Col6a3, are upregulated, and matrilysin matrix metalloproteases-7 is downregulated. Mmp7 is found in hot spot areas within the tumors of ApcMin/+ mice treated with the vehicle, but is greatly diminished in those mice treated with sulindac 2172 3.4.24.23 TAPI-1 a hydroxamate-based matrix metalloproteinase inhibitor, reduces the affinity of the enzyme for cholesterol sulfate and cardiolipin, but not for sulfatide, molecular mechanism by which TAPI-1 inhibits binding of MMP-7 to the lipids, overview 11666 3.4.24.23 thiorphan - 1128 3.4.24.23 TIMP-1 i.e. type 1 tissue inhibitor of MMPs, is elevated in colorectal tumor tissue compared to healthy mucosa 1703 3.4.24.23 TIMP-1 expression and activity of MMP-7 in fetal membranes during premature rupture of membranes is increased, while the TIMP-1 level is reduced, immunohistochemic analysis, overview 1703 3.4.24.23 TIMP-1 tissue inhibitor of metalloprotease-1 1703 3.4.24.23 TIMP-1 from gingival and dermal fibroblasts forms complexes with MMP-7 and inhibits its expression and activity 1703 3.4.24.23 TIMP-1 no apparent regulation of the expression of TIMP-1 by either tumor necrosis factor or enamel matrix derivative 1703 3.4.24.23 TIMP-2 - 1110 3.4.24.23 TIMP-3 tissue inhibitor of metalloproteinases-3 1997 3.4.24.23 TIMP-3 is induced by enamel matrix derivative 1997 3.4.24.23 TIMP-4 tissue inhibitor of metalloproteinases-4 11270 3.4.24.23 TIMP3 tissue inhibitor of metalloproteinase-3, interacts with MMP-7 75516 3.4.24.23 tissue inhibitor of metalloproteinase i.e. TIMP-1. TIMP-1 and matrilysin co-localize and co-immunoprecipitate in wounded primary airway epithelial cultures. TIMP-1-deficient cultures migrate faster, and epithelial cells spread to a greater extent compared with wild-type cultures. TIMP-1 also inhibits matrilysin-mediated cell migration and spreading in vitro. In vivo, TIMP-1 deficiency enhances airway re-epithelialization after naphthalene injury. TIMP-1 and matrilysin co-localize in airway epithelial cells adjacent to the wound edge 31091 3.4.24.23 Tissue inhibitor of metalloproteinase-1 - 5659 3.4.24.23 tissue inhibitors of metalloproteinase 1 TIMP-1 206299 3.4.24.23 Zincov - 8209 3.4.24.23 ZnCl2 - 271 3.4.24.23 [(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucyl-[(1'',1'')-diphenyl]-methylamide - 240024 3.4.24.23 [(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucyl-[(1''R)-phenyl]-ethylamide - 240023 3.4.24.23 [(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucyl-[(1''S)-phenyl]-ethylamide - 240022 3.4.24.23 [(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucylmethylamide - 240025 3.4.24.23 [(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucylphenylamide - 240021 3.4.24.23 [4-(2,4-dimethoxyphenyl)-1-phenoxy-1,4-dihydropyridine-3,5-diyl]dimethanol - 205903 3.4.24.23 [4-(3,4,5-trimethoxyphenyl)-1,4-dihydropyridine-3,5-diyl]dimethanol - 205904 3.4.24.23 [4-(4-methoxyphenyl)-1,4-dihydropyridine-3,5-diyl]dimethanol - 205906 3.4.24.23 [4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-diyl]dimethanol - 205907 3.4.24.23 [4-(4-propylphenyl)-1,4-dihydropyridine-3,5-diyl]dimethanol - 205908